- This free GMP audit checklist covers 53 requirements across 21 CFR Part 211, Subparts B to K, with Compliant, Partial, Not compliant, and N/A scoring.
- Items tagged with an FDA 483 rank are among the ten Part 211 sections FDA cited most often on drug Form 483s in fiscal year 2025.
- Your answers and notes save in your browser, and the summary ranks gaps by severity and prints to PDF.
- Use it for a first-pass self-audit before a mock inspection, customer audit, or FDA inspection.
GMP Audit Checklist (21 CFR 211)
53 questions across 10 subparts. Answers are saved on this device only.
21 CFR 211.22 to 211.34. Read the regulation on eCFR.
21 CFR 211.42 to 211.58. Read the regulation on eCFR.
21 CFR 211.63 to 211.72. Read the regulation on eCFR.
21 CFR 211.80 to 211.94. Read the regulation on eCFR.
21 CFR 211.100 to 211.115. Read the regulation on eCFR.
21 CFR 211.122 to 211.137. Read the regulation on eCFR.
21 CFR 211.142 to 211.150. Read the regulation on eCFR.
21 CFR 211.160 to 211.176. Read the regulation on eCFR.
21 CFR 211.180 to 211.198. Read the regulation on eCFR.
21 CFR 211.204 to 211.208. Read the regulation on eCFR.
Questions paraphrase 21 CFR Part 211 for self-assessment and are not a substitute for the regulation text or an independent audit. Answers are stored only in this browser.
What a GMP audit checks
A GMP audit checks whether a site's people, facilities, equipment, materials, processes, laboratories, and records meet current good manufacturing practice. For finished drugs sold in the United States, that standard is 21 CFR Part 211. Auditors do not stop at whether a procedure exists. They test whether it is followed, whether records prove it, and whether the quality unit acts when something goes wrong. That is why the checklist above asks about practice as well as paperwork.
The 21 CFR 211 sections FDA cites most often
FDA publishes counts of the regulations cited on Form 483s each year. In fiscal year 2025, the same themes led the drug list again: quality unit procedures, investigations, written procedures, and laboratory controls. The top four sections alone account for nearly a quarter of all Part 211 observations.
If you only have time for part of the checklist, start with the items tagged with an FDA 483 rank. Weak investigations under 211.192 are especially costly, because they tend to show up again in warning letters when the same failure repeats.
How to run a GMP self-audit with this checklist
- Scope it. Pick one site, building, or product line, and mark subparts that do not apply as N/A.
- Collect evidence, not opinions. For each item, pull a sample record, such as a recent batch record, cleaning log, or OOS investigation, before you answer.
- Score honestly. Use Partial whenever a procedure exists but records show it is not followed every time.
- Write the note. Record the evidence, the owner, and the next action. Notes print with your summary.
- Turn gaps into CAPAs. Prioritize Not compliant items, then Partial items on top-cited sections.
Self-audit, mock inspection, or FDA inspection?
| Self-audit | Mock inspection | FDA inspection | |
|---|---|---|---|
| Who runs it | Internal QA | Independent auditors acting as investigators | FDA investigators |
| Main goal | Find obvious gaps quickly | Test evidence and staff readiness under realistic pressure | Determine compliance; may result in a Form 483 |
| Typical blind spot | Workarounds the team no longer notices | Limited by time and sample size | None you can control |
When to bring in an outside GMP auditor
Bring in independent auditors when the checklist shows several red subparts, when an FDA or customer inspection is less than six months away, or after a Form 483 or warning letter. DES Pharma's GMP consulting team runs mock inspections and gap assessments, and our FDA remediation group supports responses and CAPA programs. For electronic records, pair this checklist with our ALCOA+ data integrity self-assessment. Medical device and combination product teams can use our ISO 13485 audit checklist.
DES Pharma runs mock inspections, gap assessments, and remediation programs for drug, biologic, and CDMO sites, with findings ranked the way investigators rank them.
Request a meetingGMP audit checklist FAQ
What is a GMP audit checklist?
A GMP audit checklist is a structured list of requirements an auditor checks to judge whether a manufacturing site follows current good manufacturing practice. For finished pharmaceuticals in the United States, the requirements come from 21 CFR Part 211, so this checklist is organized by its subparts, from personnel and facilities through laboratory controls and records.
Does this checklist cover all of 21 CFR Part 211?
It covers the core requirements in Subparts B through K, focusing on the sections FDA cites most. It does not reproduce every paragraph, and it does not cover related rules such as 21 CFR Part 11 for electronic records, Part 600 for biologics, or EU GMP. Treat it as a first pass, not a complete audit protocol.
How often should we run an internal GMP audit?
Part 211 does not set a frequency. Most manufacturers audit every subpart at least once a year and audit higher-risk areas, such as investigations, laboratory controls, cleaning, and data integrity, more often. Audit again after major changes, such as a new product, line, facility, or computer system.
How is a GMP audit different from a pre-approval inspection?
A GMP audit checks general compliance with Part 211. A pre-approval inspection is product-specific: FDA checks readiness for commercial manufacturing, whether the site matches what was filed in the NDA or ANDA, and data integrity. A strong GMP audit result is a prerequisite for a PAI, but it is not enough on its own.
Can a self-audit replace an independent audit?
No. Self-audits are valuable for finding obvious gaps, but teams tend to score their own systems generously and miss problems they work around every day. An independent auditor tests evidence the way an FDA investigator would, by pulling records, interviewing operators, and following data from instrument to report.
About DES Pharma Consulting. DES Pharma Consulting (Dynamic Engineering Solutions) supports drug, biologic, and advanced therapy developers with CMC strategy, analytical development, quality control, quality assurance, process development, and supply chain programs, from early development through commercial manufacturing. Contact our team to discuss your program.




